Only 5 days ago, on 5th November
2019, the Financial Times reported about meetings between the $55 billion market
valued global drugstore Walgreen Boots Alliance and several private equity groups.
According to the magazine, both parties evaluate a possible $70 billion
leveraged buyout (LBO), constituting the largest take-private deal ever in
history. Immediately after Bloomberg’s and Reuters’ media coverage of the rumours,
Walgreen’s share price rose 4 percent on the New York Stock Exchange implying
that investors would support the potential takeover strongly.
Figure 1. Walgreen Boots Alliance's share price development. Reprinted from Yahoo Finance, https://finance.yahoo.com/ |
Before going deeper into detail, I want to
shortly summarize and explain the basics of Private Equity (PE) firms and their
way of investing and operating. Generally, PE companies can be viewed as the fund
managers, so-called General Partners, of private equity funds which are
financed by institutional investors and high net-worth individuals, the so-called
Limited Partners. The main goal of the private equity managers is to acquire
controlling positions by engaging in buyouts of publicly listed companies in
order to take on operational roles in the firms and maximize their value. By
listing, merging or selling the restructured companies afterwards, the fund
managers and their limited partners receive their return if they were
successful. Going deeper into detail, one way to achieve the aim of delisting the
public equity of the targets are the already mentioned leveraged buyouts. LBO’s
are highly geared company acquisitions characterized by the fact that the raised
debt is not backed by the PE firm but only by the target’s future cash flows. The
purpose of this way of structured financing is the high return on equity that can
be achieved according to our understanding of the capital structure and the
impact of high debt on the equity cost of capital.
With that kind of knowledge, we can partly
explain the share appreciation of Walgreen. Firstly, the rumours about the
buyout directly imply that the target should be currently undervalued, that it can
be restructured to be more profitable in the long-term and that it should be
financially stable enough in terms of future free cash flow to repay all
occurring debt obligations. Furthermore, there is strong academic evidence for
the positive impact of leveraged buyouts on shareholder value and future
financial performance. Exemplars in favour of this kind of view are Bull (1989),
giving proof for superior post-buyout performance in comparison to pre-buyout
performance and Torabzadeh & Bertin (1987), stating that companies acquired
in LBO’s from 1982 to 1985 made statistically significant economic gains
posterior the corporate restructuring. We see that PE firms are taking
advantage of the implications of capital structure theory by buying strategically
suitable targets in combination with the increased return on equity in order to
increase shareholder value.
Although all the mentioned benefits, there is
also justifiable criticism when it comes to highly indebted company
acquisitions, especially such oversized mega deals like the Walgreen one. Concerning
the biggest risk namely the rising probability of bankruptcy due to the high
gearing, we should look at the current largest LBO ever. In 2007, a syndicate of
3 PE firms took control over the Texan power company TXU corp. for $31.8
billion (Reuters) at a point of depressed valuation with the expectation of
rising of gas prices. 7 years later in 2014, TXU declared insolvency, collapsing
under the obligations of more than $40 billion (Bloomberg) in debt. This is
exemplary demonstrating the risk that comes along with higher return on equity demands
and is in accordance with modern capital structure trade-off theory that
suggests not to lever up to such excessive levels (Kraus & Litzenberger,
1973).
In conclusion, it might seem like investors
are too enthusiastically focused on the upsides of the potential takeover. Since
the pharma giant is going through tough times as newly digital businesses in
the healthcare sector like online prescription companies are flooding the
market, the shareholders might have desperately waited for a managerial turnover
without critically questioning the full background of the deal. Furthermore, subjective
criticism could also be the arguable managerial abilities of a few non-specialist
private equity bankers to fix Walgreen’s weakened business model.
Having discussed the possible takeover, I
realized how present and important modern financial capital structure theories are
in daily business. One the one hand, the theories can be used to elucidate the cornerstone
of investment strategies like leveraged buyouts, on the other hand, models like
the trade-off theory are furthermore able to give explanations for the limitations
and risks that come along with certain capital structures (Kraus &
Litzenberger, 1973).
Bibliography
Bull, I. (1989). Financial
Performance of Leveraged Buyouts: An Empirical Analysis. Journal of
Business Venturing, 4(4), 263-279.
Fontanella-Khan, J., Vandevelde, M.,
Kuchler, H., & Massoudi, A. (2019). Walgreens Boots Alliance Explores
$70bn Buyout. Financial Times. Retrieved from https://www.ft.com/
Kraus, A., & Litzenberger, R. H.
(1973). A state‐preference model of optimal financial leverage. The
Journal of Finance, 28(4), 911-922.
Torabzadeh, K. M., & Bertin, W. J.
(1987). Leveraged Buyouts and Shareholder Returns. The Journal of
Financial Research, 10(4), 313-319.
No comments:
Post a Comment